Intracytoplasmic Sperm Injection Preparation in Infertile Women
NCT ID: NCT03824340
Last Updated: 2019-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
500 participants
INTERVENTIONAL
2019-01-30
2020-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Delayed Embryo Transfer in Poor Responders
NCT02431689
Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI
NCT02741154
Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection
NCT02306564
Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility
NCT02416596
Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
NCT03996434
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Doxycycline before ICSI
extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
Doxycycline before ICSI
Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
control group
control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline before ICSI
Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
42 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aljazeera Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mahmoud Alalfy, PhD
Role: PRINCIPAL_INVESTIGATOR
Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Algazeerah
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ahmed Elgazzar, M.D
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICSI preparation
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.